{"id":19815,"date":"2024-06-19T09:15:41","date_gmt":"2024-06-19T09:15:41","guid":{"rendered":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/nab-paclitaxel-cisplatin-and-capecitabine-versus-cisplatin-and-gemcitabine-as-first-line-chemotherapy-in-patients-with-recurrent-or-metastatic-nasopharyngeal-carcinoma-randomised-phase-3-clinical-t\/"},"modified":"2024-06-19T11:09:09","modified_gmt":"2024-06-19T11:09:09","slug":"nab-paclitaxel-cisplatin-and-capecitabine-versus-cisplatin-and-gemcitabine-as-first-line-chemotherapy-in-patients-with-recurrent-or-metastatic-nasopharyngeal-carcinoma-randomised-phase-3-clinical-t","status":"publish","type":"the-bmj-article","link":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/nab-paclitaxel-cisplatin-and-capecitabine-versus-cisplatin-and-gemcitabine-as-first-line-chemotherapy-in-patients-with-recurrent-or-metastatic-nasopharyngeal-carcinoma-randomised-phase-3-clinical-t\/","title":{"rendered":"Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with nasopharyngeal carcinoma"},"featured_media":0,"template":"","categories":[],"tags":[],"content_type":[36],"editorial_panel":[],"channel_page":[44],"class_list":["post-19815","the-bmj-article","type-the-bmj-article","status-publish","hentry","article-type-research","channel-page-research"],"aioseo_notices":[],"meta_box":{"the_bmj_article-url":"\/content\/385\/bmj-2023-077890","the_bmj_article-description":"","the_bmj_article-the_bmj_article_image":[{"width":150,"height":150,"file":"2024\/06\/Chemo-Recurrent-or-Metastatic-NP-Carcinoma-540px.png","filesize":22840,"sizes":{"medium":{"file":"Chemo-Recurrent-or-Metastatic-NP-Carcinoma-540px-300x194.png","width":300,"height":194,"mime-type":"image\/png","filesize":16293,"url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2024\/06\/Chemo-Recurrent-or-Metastatic-NP-Carcinoma-540px-300x194.png"},"thumbnail":{"file":"Chemo-Recurrent-or-Metastatic-NP-Carcinoma-540px-150x150.png","width":150,"height":150,"mime-type":"image\/png","filesize":8266,"url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2024\/06\/Chemo-Recurrent-or-Metastatic-NP-Carcinoma-540px-150x150.png"}},"image_meta":{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0","keywords":[]},"ID":"19824","name":"Chemo-Recurrent-or-Metastatic-NP-Carcinoma-540px.png","path":"\/dom34810\/wp-content\/uploads\/sites\/4\/2024\/06\/Chemo-Recurrent-or-Metastatic-NP-Carcinoma-540px.png","url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2024\/06\/Chemo-Recurrent-or-Metastatic-NP-Carcinoma-540px-150x150.png","full_url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2024\/06\/Chemo-Recurrent-or-Metastatic-NP-Carcinoma-540px.png","title":"Chemo Recurrent or Metastatic NP Carcinoma -540px","caption":"","description":"","alt":"Infographic","srcset":false}],"the_bmj_article-related_articles":[{"article_type":"","related_article_title":"","related_article_url":""}],"the_bmj_article-journal_name":""},"head_tags":[{"tag":"title","content":"Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with nasopharyngeal carcinoma | The BMJ"},{"tag":"meta","attributes":{"name":"robots","content":"max-image-preview:large"}},{"tag":"link","attributes":{"rel":"canonical","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/nab-paclitaxel-cisplatin-and-capecitabine-versus-cisplatin-and-gemcitabine-as-first-line-chemotherapy-in-patients-with-recurrent-or-metastatic-nasopharyngeal-carcinoma-randomised-phase-3-clinical-t\/"}},{"tag":"meta","attributes":{"name":"generator","content":"All in One SEO (AIOSEO) 4.9.6.2"}},{"tag":"meta","attributes":{"property":"og:locale","content":"en_GB"}},{"tag":"meta","attributes":{"property":"og:site_name","content":"The BMJ | The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"property":"og:type","content":"article"}},{"tag":"meta","attributes":{"property":"og:title","content":"Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with nasopharyngeal carcinoma | The BMJ"}},{"tag":"meta","attributes":{"property":"og:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/nab-paclitaxel-cisplatin-and-capecitabine-versus-cisplatin-and-gemcitabine-as-first-line-chemotherapy-in-patients-with-recurrent-or-metastatic-nasopharyngeal-carcinoma-randomised-phase-3-clinical-t\/"}},{"tag":"meta","attributes":{"property":"article:published_time","content":"2024-06-19T09:15:41+00:00"}},{"tag":"meta","attributes":{"property":"article:modified_time","content":"2024-06-19T11:09:09+00:00"}},{"tag":"meta","attributes":{"name":"twitter:card","content":"summary"}},{"tag":"meta","attributes":{"name":"twitter:title","content":"Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with nasopharyngeal carcinoma | The BMJ"}},{"tag":"link","attributes":{"rel":"alternate","type":"application\/rss+xml","title":"The BMJ \u00bb Feed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/feed\/"}},{"tag":"link","attributes":{"rel":"alternate","type":"application\/rss+xml","title":"The BMJ \u00bb Comments Feed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/comments\/feed\/"}},{"tag":"link","attributes":{"rel":"alternate","title":"oEmbed (JSON)","type":"application\/json+oembed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/oembed\/1.0\/embed?url=https%3A%2F%2Fbmj-chicken.bmj.com%2Fthebmj%2Fthe-bmj-article%2Fnab-paclitaxel-cisplatin-and-capecitabine-versus-cisplatin-and-gemcitabine-as-first-line-chemotherapy-in-patients-with-recurrent-or-metastatic-nasopharyngeal-carcinoma-randomised-phase-3-clinical-t%2F"}},{"tag":"link","attributes":{"rel":"alternate","title":"oEmbed (XML)","type":"text\/xml+oembed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/oembed\/1.0\/embed?url=https%3A%2F%2Fbmj-chicken.bmj.com%2Fthebmj%2Fthe-bmj-article%2Fnab-paclitaxel-cisplatin-and-capecitabine-versus-cisplatin-and-gemcitabine-as-first-line-chemotherapy-in-patients-with-recurrent-or-metastatic-nasopharyngeal-carcinoma-randomised-phase-3-clinical-t%2F&format=xml"}},{"tag":"link","attributes":{"rel":"https:\/\/api.w.org\/","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/"}},{"tag":"link","attributes":{"rel":"alternate","title":"JSON","type":"application\/json","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article\/19815"}},{"tag":"link","attributes":{"rel":"EditURI","type":"application\/rsd+xml","title":"RSD","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/xmlrpc.php?rsd"}},{"tag":"meta","attributes":{"name":"generator","content":"WordPress 6.9.4"}},{"tag":"link","attributes":{"rel":"shortlink","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/?p=19815"}},{"tag":"meta","attributes":{"property":"og:locale","content":"en_GB"}},{"tag":"meta","attributes":{"property":"og:site_name","content":"The BMJ"}},{"tag":"meta","attributes":{"property":"og:title","content":"Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with nasopharyngeal carcinoma"}},{"tag":"meta","attributes":{"property":"og:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/nab-paclitaxel-cisplatin-and-capecitabine-versus-cisplatin-and-gemcitabine-as-first-line-chemotherapy-in-patients-with-recurrent-or-metastatic-nasopharyngeal-carcinoma-randomised-phase-3-clinical-t\/"}},{"tag":"meta","attributes":{"property":"og:type","content":"article"}},{"tag":"meta","attributes":{"property":"og:description","content":"The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"name":"twitter:title","content":"Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with nasopharyngeal carcinoma"}},{"tag":"meta","attributes":{"name":"twitter:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/nab-paclitaxel-cisplatin-and-capecitabine-versus-cisplatin-and-gemcitabine-as-first-line-chemotherapy-in-patients-with-recurrent-or-metastatic-nasopharyngeal-carcinoma-randomised-phase-3-clinical-t\/"}},{"tag":"meta","attributes":{"name":"twitter:description","content":"The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"name":"twitter:card","content":"summary_large_image"}}],"_links":{"self":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article\/19815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article"}],"about":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/types\/the-bmj-article"}],"type":[{"embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/types\/the-bmj-article"}],"wp:attachment":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/media?parent=19815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/categories?post=19815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/tags?post=19815"},{"taxonomy":"article-type","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/content_type?post=19815"},{"taxonomy":"editorial-panel","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/editorial_panel?post=19815"},{"taxonomy":"channel-page","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/channel_page?post=19815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}